iBio (IBIO) Operating Leases (2021 - 2026)

iBio (IBIO) has reported Operating Leases for 6 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 24.87% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 24.87% decrease from a year earlier, with the FY2026 full-year figure at $1.7 million, down 24.87% from the prior year.
• Operating Leases was $1.7 million for Q2 2026 at iBio, down from $1.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $5.5 million in Q1 2022 and troughed at $1.7 million in Q2 2026.
• A 5-year average of $2.8 million and a median of $2.7 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases dropped 1.01% in 2022 and slumped 41.87% in 2023, its largest moves.
• Over 5 years, Operating Leases stood at $3.3 million in 2022, then retreated by 12.39% to $2.9 million in 2023, then declined by 15.87% to $2.4 million in 2024, then dropped by 21.14% to $1.9 million in 2025, then fell by 14.49% to $1.7 million in 2026.
• The last three Operating Leases figures came in at $1.7 million (Q2 2026), $1.8 million (Q1 2026), and $1.9 million (Q4 2025), per Business Quant data.